

Review Form 1.7

Journal Name:	Asian Journal of Research in Medical and Pharmaceutical Sciences
Manuscript Number:	Ms_AJRIMPS_97834
Title of the Manuscript:	“Health Economic Evaluations for Alzheimer’s Disease: Pathophysiology, Diagnosis and Pharmacological Approaches”
Type of the Article	Review Article

General guideline for Peer Review process:

This journal’s peer review policy states that **NO** manuscript should be rejected only on the basis of **‘lack of Novelty’**, provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalajrimps.com/index.php/AJRIMPS/editorial-policy>)

Review Form 1.7

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<p><u>Compulsory</u> REVISION comments</p> <p>1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript)</p> <p>2. Is the title of the article suitable? (If not please suggest an alternative title)</p> <p>3. Is the abstract of the article comprehensive?</p> <p>4. Are subsections and structure of the manuscript appropriate?</p> <p>5. Do you think the manuscript is scientifically correct?</p> <p>6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form.</p> <p><u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u></p>	<p>1. Yes;</p> <p>2. Yes;</p> <p>3. in parts (suggestions will be mention bellow);</p> <p>4. Missing the chapter on methods and also the objective of the study at the end of the introduction;</p> <p>5. Yes;</p> <p>6. Perfect.</p>	
<p><u>Minor</u> REVISION comments</p> <p>1. Is language/English quality of the article suitable for scholarly communications?</p>		
<p><u>Optional/General</u> comments</p>	<p>Authors should review all the English language used in the paper. As an example of the sample below for the abstract:</p>	

Review Form 1.7

Alois Alzheimer first identified Alzheimer disease (AD) in 1907 as a slowly progressing form of dementia that affects cognition, behaviour, and functional status. It is distinguished by the intraneuronal deposits of neurofibrillary tangles(NFTs) and extracellular amyloid b (Ab) plaques. The basis of manifestation of AD is two type- Early-onset Alzheimer's disease (EOAD), Late-onset Alzheimer's disease (LOAD). EOAD occur before 65 years of age and is related Mendelian inheritance, which cause mutation in APP, PSEN1 or PSEN2. So it is familial AD. While LOAD occur after age 65 years of age and these is no related to genetic cause. So it is sporadic AD. Screening tests like the MMSE and the Montreal Cognitive Assessment are used to help with evaluation and tracking the rate and pattern of cognitive decline. Clinical biomarker testing is now available to assist physicians in determining the presence and extent of AD pathologic changes, as well as their downstream effects. Amyloid PET allows for the detection of fibrillar (plaque) amyloid. Although though AD is a public health concern, only two pharmacological classes are currently approved to treat AD: antagonists of N-methyl d-aspartate and inhibitors of the cholinesterase enzyme (naturally occurring, synthetic, and hybrid variants) (NMDA). Reduced acetylcholine (ACh) production is the cause of

AD. One of the therapeutic approaches that improves cognitive and neural cell performance is increasing cholinergic levels by inhibiting acetylcholinesterase. The first cholinesterase inhibitor medicine for the treatment of AD that the FDA (Food and Drug Administration) approved was tacrine.

• GRAMMAR

~~Alzheimer~~ → Alzheimer's

It seems that this noun form may be incorrect.

Review Form 1.7

• CONVENTIONS

~~behaviour~~ → behavior

The spelling of **behaviour** is a non-American variant. For consistency, consider replacing it with the American English spelling.

• GRAMMAR

~~type~~ → types

It seems that **type** may not agree in number with other words in this phrase.

• GRAMMAR

~~occur~~ → occurs

It seems that the verb **occur** does not agree with the subject. Consider changing the verb form.

• GRAMMAR

to Mendelian

It seems that preposition use may be incorrect here.

Review Form 1.7

- GRAMMAR

~~cause~~ → **causes**

The plural verb **cause** does not appear to agree with the singular subject **Mendelian inheritance**. Consider changing the verb form for subject-verb agreement.

- GRAMMAR

a mutation

The noun phrase **mutation** seems to be missing a determiner before it. Consider adding an article.

- PUNCTUATION

, or

It seems that this sentence contains a series of three or more words, phrases, or clauses. Consider inserting a comma to separate the elements.

- PUNCTUATION

, and

It seems that you are missing a comma. Consider adding a comma.

- SPELLING

~~no~~ → **not**

The word **no** doesn't seem to fit this context. Consider replacing it with a different one.

Review Form 1.7

• GRAMMAR

~~these is~~ → **it is**

It seems that there is a pronoun problem here.

• GRAMMAR

a genetic

The noun phrase **genetic cause** seems to be missing a determiner before it. Consider adding an article.

• GRAMMAR

the evaluation

It seems that there is an article usage problem here.

• GRAMMAR

of the

It seems that preposition use may be incorrect here.

• GRAMMAR

though

It seems that conjunction use may be incorrect here.

• GRAMMAR

~~improves~~ → improve

The singular verb **improves** does not appear to agree with the plural subject **the therapeutic approaches**. Consider changing the verb form for subject-verb agreement.

• CLARITY

Your sentence may be unclear or hard to follow. Consider rephrasing.

*Although AD is a public health concern, only two pharmacological classes are currently approved to treat AD: antagonists of N-methyl d-aspartate and ~~inhibitors of the cholinesterase-enzyme~~ **cholinesterase enzyme inhibitors** (naturally occurring, synthetic, and hybrid variants) (NMDA).*

• CLARITY

Your sentence may be unclear or hard to follow. Consider rephrasing.

*One ~~of the therapeutic approaches that improve~~ **therapeutic approach that improves** cognitive and neural cell performance is increasing cholinergic levels by inhibiting acetylcholinesterase.*

• CONCISENESS

~~the treatment of~~ → treating

The phrase **the treatment of** may be wordy. Consider changing the wording.

Title and keywords

It is not recommended to repeat words in the title and keywords. This reduces the chance of the work

Review Form 1.7

	<p>being found on journal platforms and databases.</p> <p>Introduction and others Several spacing errors between words were found in the text. The references in the figures and tables need to be included. The study's objective needed to be included in the last paragraph of the introduction. After the introduction, it would be interesting to have a methods chapter explaining: the keywords used in the search, platforms or databases explored, selection criteria for papers, the period in which the selection of papers was carried out, and how many were initially selected, how many were cut and why.</p>	
--	--	--

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Luis Carlos Oliveira Gonçalves
Department, University & Country	Federal University of Mato Grosso, Brazil